Effects of oral paricalcitol therapy on arterial stiffness and osteopontin in hypertensive patients with chronic kidney disease and secondary hyperparathyroidism

Go, 2004, Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization, N Engl J Med, 351, 1296, 10.1056/NEJMoa041031 Levin, 2007, Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease, Kidney Int, 71, 31, 10.1038/sj.ki.5002009 Li, 2002, 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system, J Clin Invest, 110, 229, 10.1172/JCI0215219 Teng, 2005, Activated injectable vitamin D and hemodialysis survival: A historical cohort study, J Am Soc Nephrol, 16, 1115, 10.1681/ASN.2004070573 Teng, 2003, Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy, N Engl J Med, 349, 446, 10.1056/NEJMoa022536 Duplancic, 2013, The influence of selective vitamin D receptor activator paricalcitol on cardiovascular system and cardiorenal protection, Clin Interv Aging, 8, 149 Sprague, 2003, Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism, Kidney Int, 63, 1483, 10.1046/j.1523-1755.2003.00878.x Mizobuchi, 2007, Differential effects of vitamin D receptor activators on vascular calcification in uremic rats, Kidney Int, 72, 709, 10.1038/sj.ki.5002406 Kaess, 2012, Aortic stiffness, blood pressure progression, and incident hypertension, JAMA, 308, 875, 10.1001/2012.jama.10503 Roman, 2009, High central pulse pressure is independently associated with adverse cardiovascular outcome the strong heart study, JACC, 54, 1730, 10.1016/j.jacc.2009.05.070 London, 2001, Arterial wave reflections and survival in end-stage renal failure, Hypertension, 38, 434, 10.1161/01.HYP.38.3.434 London, 2007, Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency, J Am Soc Nephrol: JASN, 18, 613, 10.1681/ASN.2006060573 Mahmud, 2005, Arterial stiffness is related to systemic inflammation in essential hypertension, Hypertension, 46, 1118, 10.1161/01.HYP.0000185463.27209.b0 Sodek, 2000, Osteopontin, Crit Rev Oral Biol Med, 11, 279, 10.1177/10454411000110030101 Scatena, 2007, Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease, Arterioscler Thromb Vasc Biol, 27, 2302, 10.1161/ATVBAHA.107.144824 Ohmori, 2003, Plasma osteopontin levels are associated with the presence and extent of coronary artery disease, Atherosclerosis, 170, 333, 10.1016/S0021-9150(03)00298-3 Tousoulis, 2013, Serum osteoprotegerin and osteopontin levels are associated with arterial stiffness and the presence and severity of coronary artery disease, Int J Cardiol, 167, 1924, 10.1016/j.ijcard.2012.05.001 Lorenzen, 2010, Circulating levels of osteopontin are closely related to glomerular filtration rate and cardiovascular risk markers in patients with chronic kidney disease, Eur J Clin Invest, 40, 294, 10.1111/j.1365-2362.2010.02271.x James, 2014, 2014 Evidence-based guideline for the management of high blood pressure in adults. Report from the panel members appointed to the Eighth Joint National Committee (JNC 8), JAMA, 311, 507, 10.1001/jama.2013.284427 Tsioufis, 2000, Absence of any significant effects of circadian blood pressure variations on carotid artery elastic properties in essential hypertensive subjects, J Hum Hypertens, 14, 813, 10.1038/sj.jhh.1001115 National Kidney Foundation, 2002, K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification, Am J Kidney Dis, 39, S1 2007 Guidelines for the Management of Arterial Hypertension, 2007, The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC), J Hypertens, 25, 1105, 10.1097/HJH.0b013e3281fc975a Tsioufis, 2005, Left ventricular diastolic dysfunction is accompanied by increased aortic stiffness in the early stages of essential hypertension: a TDI approach, J Hypertens, 23, 1745, 10.1097/01.hjh.0000174394.57644.69 Zoccali, 2014, Paricalcitol and endothelial function in chronic kidney disease trial, Hypertension, 64, 1005, 10.1161/HYPERTENSIONAHA.114.03748 Thadhani, 2012, Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial, JAMA, 307, 674, 10.1001/jama.2012.120 Georgiadou, 2010, Osteopontin as a novel prognostic marker in stable ischaemic heart disease: a 3-year follow-up study, Eur J Clin Invest, 40, 288, 10.1111/j.1365-2362.2010.02257.x Barreto, 2011, Prognostic implication of plasma osteopontin levels in patients with chronic kidney disease, Nephron Clin Pract, 117, c363, 10.1159/000321520 Thethi, 2015, Effect of paricalcitol on endothelial function and inflammation in type 2 diabetes and chronic kidney disease, J Diabet Complicat, 29, 433, 10.1016/j.jdiacomp.2015.01.004 Navarro-González, 2013, Anti-inflammatory profile of paricalcitol in hemodialysis patients: a prospective, open-label, pilot study, J Clin Pharmacol, 53, 421, 10.1002/jcph.19 Wortsman, 2000, Decreased bioavailability of vitamin D in obesity, Am J Clin Nutr, 72, 690, 10.1093/ajcn/72.3.690 Scott, 2015, Vitamin D and physical activity status: associations with five-year changes in body composition and muscle function in community-dwelling older adults, J Clin Endocrinol Metab, 100, 670, 10.1210/jc.2014-3519 deZeeuw, 2011, Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial, Lancet, 376, 1543, 10.1016/S0140-6736(10)61032-X Lundwall, 2015, Paricalcitol, Microvascular and endothelial function in non-diabetic chronic kidney disease: a randomized trial, Am J Nephrol, 42, 265, 10.1159/000441364 Goodman, 1994, Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy, Kidney Int, 46, 1160, 10.1038/ki.1994.380 Avram, 2001, Importance of low serum intact parathyroid hormone as a predictor of mortality in hemodialysis and peritoneal dialysis patients: 14 years of prospective observation, Am J Kidney Dis, 38, 1351, 10.1053/ajkd.2001.29254 Lazaros, 2016, The impact of renal dysfunction on the outcome of patients with myocardial infarction: does gender really matter?, Hellenic J Cardiol, 57, 116, 10.1016/j.hjc.2016.04.002 Savic, 2016, Gender differences in the prognostic impact of chronic kidney disease in patients with left ventricular systolic dysfunction following ST elevation myocardial infarction treated with primary percutaneous coronary intervention, Hellenic J Cardiol, 57, 109, 10.1016/j.hjc.2015.11.001